Keep Antibiotics Working campaign success survey launched

Keep Antibiotics Working campaign success survey launched

January 16 2018 Community pharmacists in Scotland are being asked for their views on the recent...

MHRA warns of confusion over drug names and potential for errors

MHRA warns of confusion over drug names and potential for errors

January 11 2018 Healthcare professionals are being asked to be extra vigilant when dispensing or...

Co-dydramol strengths and herbal medicines among latest Drug Safety Update advice

Co-dydramol strengths and herbal medicines among latest Drug Safety Update advice

January 10 2018 The medicines regulator has highlighted the different strengths of co-dydramol in...

Pharmacist Support announces five new trustees

Pharmacist Support announces five new trustees

January 9 2018 Five new trustees have been appointed by Pharmacist Support, the independent...

NHS England promoting new round of applications for practice pharmacists

NHS England promoting new round of applications for practice pharmacists

January 9 2018 NHS England is urging general practices to consider recruiting pharmacists to work...

  • Keep Antibiotics Working campaign success survey launched

    Keep Antibiotics Working campaign success survey launched

    Tuesday, 16 January 2018 13:25
  • MHRA warns of confusion over drug names and potential for errors

    MHRA warns of confusion over drug names and potential for errors

    Thursday, 11 January 2018 12:35
  • Co-dydramol strengths and herbal medicines among latest Drug Safety Update advice

    Co-dydramol strengths and herbal medicines among latest Drug Safety Update advice

    Wednesday, 10 January 2018 15:57
  • Pharmacist Support announces five new trustees

    Pharmacist Support announces five new trustees

    Tuesday, 09 January 2018 11:41
  • NHS England promoting new round of applications for practice pharmacists

    NHS England promoting new round of applications for practice pharmacists

    Tuesday, 09 January 2018 11:36

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a alert imageJanuary 10 2018

The medicines regulator has highlighted the different strengths of co-dydramol in its latest Drug Safety Update. 

For many years co-dydramol has been available at a fixed ratio of 1:50, combining dihydrocodeine 10mg and paracetamol 500mg. However, the MHRA’s latest DSU is advising that new strengths containing greater amounts of dihydrocodeine – co-dydramol 20/500 mg and co-dydramol 30/500 mg tablets – are becoming available.

Health professionals should take care to ensure the intended strength is clearly prescribed and the correct strength is dispensed, says the MHRA. If the prescribed strength is unclear, the person dispensing should contact the prescriber for clarification. It is also asking that health professionals “report suspected adverse drug reactions with opioids, including any harm from medication error, via the Yellow Card Scheme.”

The January 6 DSU newsletter also asks health professionals to ask if a patient has been using herbal medicines when reporting any suspected adverse drug reaction. If herbal medicines or traditional Chinese medicines have been used, this information should be included on the Yellow Card scheme report.

Ideally, information about a herbal product should include the brand name, the list of ingredients, a copy of the package labelling if available, and any manufacturer details. Patients should also be advised to check for the Traditional Herbal Registration Certification Mark.

Another medicine included in the DSU newsletter is daclizumab (daclizumab beta), which is “now restricted to adults with relapsing multiple sclerosis who have had an inadequate response to at least two other disease-modifying therapies (DMTs) and for whom other DMTs are contraindicated or unsuitable.”

The MHRA is advising that patients with pre-existing hepatic disease or hepatic impairment should not use daclizumab. Caution should also be taken in prescribing daclizumab “in patients receiving other medication that may be hepatotoxic, including over-the-counter products and herbal medicines.”

Links:
MHRA Drug Safety Update: monthly PDF newsletters        
MHRA Drug Safety Update: monthly PDF newsletter. January 6 2018. 11;6.                 
Co-dydramol DSU             
Herbal medicines DSU    
Daclizumab DSU                

Practice News

January 18 2018 Pharmacists are being urged to express their views on the impact of UK-wide proposals to reschedule pregabalin and gabapentin as controlled drugs.
January 18 2018 Delays in releasing funding promised to support community pharmacy’s role in integrated care is contributing to the current hospital pressures, Sandra Gidley has warned.